Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

UPDATE: Canaccord Genuity Initiates Coverage on Lpath on iSONEP Potential


In a report published Wednesday, Canaccord Genuity analyst John Newman initiated coverage on Lpath (NASDAQ: LPTN) with a Buy rating and $17.00 price target.

In the report, Canaccord Genuity noted, “We are initiating coverage of Lpath with a BUY rating and $17 price target. Lpath's iSONEP could be paradigm changing in wet AMD with $2.4B peak sales potential. The name is still under the radar, with Lpath developing a novel wet AMD treatment that targets the underlying cause, unlike current standard of care which focuses on symptom treatment.”

Lpath closed on Tuesday at $4.25.

Latest Ratings for LPTN

Apr 2014Initiates Coverage onBuy
Nov 2013Initiates Coverage onBuy
Dec 2012Initiates Coverage onBuy

View More Analyst Ratings for LPTN
View the Latest Analyst Ratings

Posted-In: Canaccord Genuity John NewmanAnalyst Color Initiation Analyst Ratings


Related Articles (LPTN)

View Comments and Join the Discussion!

Latest Ratings

UBERInitiates Coverage On50.0
KINInitiates Coverage On14.0
CVETInitiates Coverage On30.0
ATRAInitiates Coverage On41.0
ALLOInitiates Coverage On27.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Morning Market Movers

Will Amazon's New Smartphone Feature 'Point & Shop?'